During the past decade, Nagasaki University Hospital conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 14 clinical trials were completed, i.e. on average, 38.9% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 12 clinical trials were completed. i.e. 52.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nagasaki University Hospital" #1 sponsor was "Amgen" with 7 trials, followed by "Boehringer Ingelheim" with 6 trials sponsored, "Galapagos NV" with 3 trials sponsored, "Janssen Pharmaceutical K.K." with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nagasaki University Hospital" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator, "Amgen Astellas Biopharma K.K." with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Nagasaki University Hospital" are "Prostatic Neoplasms" (4 trials), "Rheumatoid Arthritis" (3 trials), "Ulcerative Colitis" (3 trials), "Crohn's Disease" (2 trials) and "Dermatomyositis" (2 trials). Many other conditions were trialed in "Nagasaki University Hospital" in a lesser frequency.

Most popular intervention types in "Nagasaki University Hospital" are "Drug" (44 trials), "Biological" (5 trials), "Other" (3 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Enzalutamide" (4 trials), "Filgotinib" (4 trials), "Nintedanib" (3 trials) and "Pembrolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Nagasaki University Hospital" are 38 trials for "All" genders, 5 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Nagasaki University Hospital". undefined are not yet recruiting, 12 are recruiting, 12 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 16 completed trials in Nagasaki University Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Nagasaki University Hospital, 3 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".